New drug aims to extend life in tough stomach cancer

NCT ID NCT07518147

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This Phase 3 trial tests a new drug called BL-M05D1 against standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). The study will include 438 adults who have already tried one prior treatment. The goal is to see if the new drug helps people live longer or keeps the cancer from growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M05D1 (a targeted drug)
What this could lead to: If successful, this could offer a new, more effective treatment option for people with advanced gastric cancer that has stopped responding to first-line therapy.
What could go wrong: This is a Phase 3 trial, but the drug is still experimental. It may not improve survival or could have side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.